Loading... Please wait...

CoproELISA Blastocystis Assay Kit

Hover over image to zoom

$450.00
SKU:
714-01

 Product Description

Package insert view pdf
 

 

CoproELISA Blastocystis Assay Kit:
For Research Use Only
Size:  1x96 wells
Sensitivity:  Cut-Off Control
Incubation Time:  < 3 hours
Sample Type:  Stool
Sample Size: 0.1 to 0.3g

Product Developed and Manufactured by Savyon Diagnostics


Intended Use
This Eagle Biosciences CoproELISATM Blastocystis test is an Enzyme-Linked Immunosorbent Assay (ELISA) for detection of Blastocystis antigens in human fecal specimens collected from patients with gastrointestinal symptoms. The test can be used for fecal specimens submitted for routine clinical testing from adults or children. The Eagle Biosciences CoproELISATM Blastocystis ELISA is for Research Use Only and is not intended for diagnostic or therapeutic purposes. 

Background

Blastocystis is an enteric protozoan parasite of humans and a variety of other animals (1,2). It has a worldwide distribution and is often the most commonly isolated organism in parasitological surveys (3). Early studies associated Blastocystis infections with symptoms such as abdominal pain, diarrhea, constipation, fatigue, headaches, and depression (4). Subsequent reports added skin rash and joint pain to the list (5-7). The Center for Disease Control (CDC) states that the symptoms reported to be associated with Blastocystosis infection are diarrhea, watery or loose stools, anal itching, abdominal pain, weight loss, and excess gas (CDC Fact Sheet (8)). This wide array of non-specific symptoms has confounded the understanding of the potential pathogenicity of Blastocystis species. As a result, many of these infections likely go undiagnosed. Detection of Blastocystis is routinely performed by methods such as microscopy, culture, and formyl acetate concentration technique (FECT). Yet, these methods all have flaws that make them unreliable or time consuming. Since Blastocystis has several morphological forms (vacuolar, cyst, amoeboid, granular, multivacuolar, and avacuolar), microscopy is very difficult (1). In addition, FECT is unreliable because it destroys the multivacuolar, vacuolar, and granular forms of the parasite during stool processing (9). Culture requires 2–3 days to diagnosis and in some instances allows preferential growth of one subtype over another if more than one subtype is present in the stool (10). Nevertheless, microscopy and culture are believed to be the “gold standard” methods for detection of Blastocystis.

Assay Principle

Plates are coated with specific polyclonal antibodies directed against Blastocystis antigens. Fecal sample to be tested is diluted in stool diluent and incubated with the pre-coated plate. In this step Blastocystis antigens are bound to the immobilized antibodies. Non-specific antigens are removed by washing. Anti-Blastocystis polyclonal antibody conjugated to horseradish peroxidase (HRP) is added and incubated. In this step the HRP-conjugate is bound to the pre-bound antigen-antibody complex. Unbound conjugate is removed by washing. Upon the addition of TMB-substrate, the substrate is hydrolyzed by the peroxidase, yielding a blue solution of the reduced substrate. Upon the addition of the stop solution, the blue color turns yellow and should be read by an ELISA reader at a wavelength of 450/620 nm. The absorbance is proportional to the number of Blastocystis cells present in the sample.

Cross Reaction

The CoproELISATM Blastocystis test was evaluated using stool specimens defined as positive for a various gastrointestinal pathogens. No cross-reactivity or interference by mixed infection with any of the pathogens listed: G. lamblia, Cryptosporidium spp., I. Butschlii, E. vermicularis, C. cayetanesis, D. fragilis, E. histolytica/dispar, E. nana, E. hartmanni, T. trichiura, E. coli & B. coli.

References

  1. Stenzel DJ, Boreham PF., Blastocystis hominis revisited. Clin Microbiol Rev. 9(4):563-84 (1996)
  2. Tan KS., Blastocystis in humans and animals: new insights using modern methodologies. Vet Parasitol. 126(1-2):121-44 (2004)
  3. Tan KS., New Insights on Classification, Identification, and Clinical Relevance of Blastocystis spp. Clin Microbiol Rev. 21(4):639-65 (2008
  4. Qadri SM, al-Okaili GA, al-Dayel F. Clinical significance of Blastocystis hominis. J Clin Microbiol. 27(11):2407-9 (1989)
  5. Krüger K, Kamilli I, Schattenkirchner M. Blastocystis hominis as a rare arthritogenic pathogen. A case report. Z Rheumatol. 53(2):83-5. (1994)
  6. Pasqui AL, Savini E, Saletti M, Guzzo C, Puccetti L, Auteri A. Chronic urticaria and Blastocystis hominis infection: a case report. Eur Rev Med Pharmacol Sci. 8(3):117-20 (2004)
  7. Biedermann T, Hartmann K, Sing A, Przybilla B. Hypersensitivity to non-steroidal anti-inflammatory drugs and chronic urticaria cured by treatment of Blastocystis hominis infection. Br J Dermatol. 146(6):1113-4 (2002)
  8. http://www.cdc.gov/ncidod/dpd/parasites/ blastocystishominis/factsht_blastocystis_hominis.htm
  9. O'Gorman MA, Orenstein SR, Proujansky R, Wadowsky RM, Putnam PE, Kocoshis SA. Prevalence and characteristics of Blastocystis hominis infection in children. Clin Pediatr. 32(2):91-6 (1993)
  10. Direct characterization of Blastocystis from faeces by PCR and evidence of zoonotic potential. Parasitology. 134(3):359-67 (2007).

 

 Find Similar Products by Category

Vendors Other Products

Eagle Biosciences, Inc.
20A NW Blvd., Suite 112
Nashua, NH 03063
Email: info@eaglebio.com
Toll Free: 866-411-8023
International: +617-419-2019

Click the button below to add the CoproELISA Blastocystis Assay Kit to your wish list.